Can I Take Ashwagandha with Enclomiphene Citrate?

What Enclomiphene Citrate Actually Does

Enclomiphene citrate is the trans-isomer of clomiphene, separated from its cis-counterpart (zuclomiphene) to retain estrogen receptor antagonism while reducing estrogenic side effects. It blocks estrogen receptors at the hypothalamus, which removes the negative-feedback signal that keeps GnRH pulsatility suppressed. The result is a rise in LH and FSH, which drives Leydig cell testosterone synthesis.

The HPG Axis Mechanism

In a randomized, double-blind trial published in the International Journal of Impotence Research (N=163), 12.5 mg and 25 mg daily enclomiphene restored serum testosterone to normal range (>300 ng/dL) in 75% and 79% of men with secondary hypogonadism, respectively, while maintaining sperm concentration [1]. That matters clinically: exogenous testosterone suppresses spermatogenesis, but enclomiphene does not, because it works through the hypothalamic-pituitary-gonadal (HPG) axis rather than replacing endogenous hormone.

Why the SERM Mechanism Matters for Supplement Interactions

Because enclomiphene works upstream of the testes, anything that independently alters LH, FSH, testosterone, or estradiol can shift the dose-response relationship. Ashwagandha does exactly that, through a separate pathway. Understanding both mechanisms side-by-side is how you assess the actual clinical risk.

Typical Dosing and Off-Label Status

The FDA reviewed enclomiphene (brand name Androxal) and declined to approve it for secondary hypogonadism in 2013, citing trial design issues rather than safety signals [2]. Prescribers use it off-label, typically at 12.5 mg to 25 mg orally once daily. Because it is off-label, no official prescribing information addresses supplement co-administration, which is part of why patients ask this question.

How Ashwagandha Works and Why It Overlaps

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen. Its primary bioactive compounds, the withanolides, modulate the hypothalamic-pituitary-adrenal (HPA) axis, reduce cortisol, and appear to stimulate testosterone through a pathway that may involve DHEA-S and LH [3].

Testosterone-Raising Effects of Ashwagandha

A randomized, double-blind, placebo-controlled study in 57 healthy men (8 weeks, KSM-66 ashwagandha 300 mg twice daily) found a 14.7% increase in serum testosterone and an 18% improvement in DHEA-S compared with placebo [4]. A separate trial in 46 male infertility patients (90 days, root extract 675 mg/day in three divided doses) showed a 17% rise in testosterone alongside significant increases in LH [5].

That LH increase is the pharmacodynamic overlap point. Enclomiphene also raises LH. Both agents pushing LH upward through different mechanisms could produce a larger-than-expected testosterone response. This is not automatically dangerous, but it means your testosterone target range may be hit at a lower enclomiphene dose than your prescriber anticipated.

Cortisol Reduction and HPA-HPG Cross-Talk

The HPA and HPG axes are not isolated. Chronic elevation of cortisol suppresses GnRH pulsatility and reduces Leydig cell sensitivity to LH [6]. Ashwagandha's documented cortisol reduction is clinically meaningful: in a 60-day randomized controlled trial (N=64), KSM-66 at 300 mg twice daily reduced serum cortisol by 27.9% compared with placebo (P<0.001) [7].

By reducing cortisol-driven HPG suppression, ashwagandha may make the hypothalamus more responsive to enclomiphene's estrogen receptor blockade. The net effect is additive, not synergistic in a dangerous pharmacological sense, but it is a real physiological amplification.

Ashwagandha and Thyroid Hormones

A randomized controlled trial (N=50, 8 weeks, 600 mg/day ashwagandha root extract) reported statistically significant increases in serum T3 (18.6% rise) and T4 (9.3% rise) compared with placebo in subclinical hypothyroid patients [8]. Even in euthyroid adults, smaller increases in thyroid hormones have been observed.

This matters for enclomiphene users because thyroid hormones regulate sex-hormone-binding globulin (SHBG). Elevated T4 increases hepatic SHBG synthesis, which can reduce free testosterone even when total testosterone rises [9]. If ashwagandha raises T4 while enclomiphene is raising total testosterone, the net change in free testosterone may be smaller than expected from total testosterone alone. A free testosterone and SHBG panel gives a cleaner picture than total testosterone in isolation.

Is This a Pharmacokinetic Interaction?

The short answer: no evidence of one exists. Pharmacokinetic interactions occur when one substance alters the absorption, distribution, metabolism, or elimination of another.

CYP450 Profile of Enclomiphene

Clomiphene (and by extension enclomiphene) is primarily metabolized by CYP3A4 and CYP2D6 [10]. Ashwagandha withanolides have been studied in vitro for CYP inhibition. A 2015 study in Drug Metabolism and Disposition found that withaferin A and withanolide D showed minimal inhibition of CYP3A4 at physiologically relevant concentrations [11]. No clinically significant CYP-mediated interaction between ashwagandha and enclomiphene has been reported in the literature as of the date of this article.

P-glycoprotein and Transporter Considerations

P-glycoprotein (P-gp) is a drug efflux transporter relevant to several SERMs. Current in vitro data do not demonstrate meaningful P-gp inhibition by standard ashwagandha doses. Oral bioavailability of enclomiphene is not expected to change with typical supplement doses of ashwagandha (300 to 600 mg/day of root extract standardized to 5% withanolides).

The absence of a documented pharmacokinetic interaction does not mean the combination is unremarkable. The pharmacodynamic overlap described above is the real clinical concern.

The Pharmacodynamic Interaction: What Actually Happens

When you layer a SERM that raises LH on top of an adaptogen that also raises LH and simultaneously reduces cortisol, the HPG axis receives two pro-gonadotropic signals from different angles.

A Three-Axis Framework for Evaluating This Combination

The following framework organizes the overlapping effects of enclomiphene and ashwagandha across the three hormone axes most likely to be affected:

Axis 1: HPG (testosterone production)

• Enclomiphene raises LH by blocking hypothalamic estrogen receptors.
• Ashwagandha raises LH through a mechanism that may involve direct pituitary stimulation and reduced cortisol suppression of GnRH.
• Combined effect: additive upward pressure on LH and testosterone. Monitor for testosterone above the upper limit of the reference range (>1050 ng/dL in most labs), which can increase erythrocytosis risk and estradiol conversion.

Axis 2: HPA (cortisol and stress response)

• Enclomiphene has no direct adrenal action. However, androgens and estrogens modulate HPA sensitivity; changing gonadal hormone levels with enclomiphene may marginally alter cortisol feedback.
• Ashwagandha directly reduces cortisol output. The 27.9% reduction seen in trials translates to a meaningful HPA shift at 600 mg/day.
• Combined effect: net cortisol reduction. Beneficial for most patients with hypogonadism linked to chronic stress, but verify that morning cortisol does not fall below 10 mcg/dL, a threshold that may warrant adrenal function evaluation.

Axis 3: Thyroid

• Enclomiphene does not directly affect thyroid hormone production. Testosterone itself can slightly reduce SHBG, which complicates interpretation of thyroid-binding globulin-bound T4.
• Ashwagandha may raise T3 and T4.
• Combined effect: SHBG interpretation becomes more complex. Use free testosterone and free T4 for monitoring rather than total values alone.

Who Should Be Most Cautious

Most men taking enclomiphene for secondary hypogonadism can use ashwagandha without serious risk, but three subgroups warrant closer supervision.

Men with Thyroid Disease

Patients with Hashimoto's thyroiditis or any treated thyroid condition taking levothyroxine (T4 replacement) face a more complex interaction. Ashwagandha-driven increases in endogenous T3 and T4 could reduce levothyroxine requirements, potentially causing iatrogenic hyperthyroidism if dosing is not adjusted. A 2022 case series documented three patients on levothyroxine who developed suppressed TSH after adding ashwagandha without informing their prescriber [12]. These patients were not on enclomiphene, but the thyroid signal is real.

Men with Polycythemia Risk

Elevated testosterone from any source, including the combination described here, raises red blood cell production through erythropoietin stimulation. The American Urological Association guideline on testosterone therapy notes that hematocrit above 54% requires dose reduction or discontinuation of testosterone-raising therapy [13]. Men with baseline hematocrit above 48% or those with sleep apnea (an independent erythrocytosis risk factor) should check a CBC at baseline and at 6 weeks.

Men Taking Other CYP3A4-Relevant Medications

If you take statins (atorvastatin, simvastatin), certain antifungals, or HIV antiretrovirals alongside enclomiphene and ashwagandha, your CYP3A4 load is already significant. Although ashwagandha's CYP3A4 inhibition appears modest, stacking multiple partial inhibitors can produce additive enzyme inhibition. Disclose all medications to your prescriber.

Monitoring Protocol for the Enclomiphene-Ashwagandha Combination

Standard enclomiphene monitoring includes testosterone and LH at 4 to 6 weeks after dose initiation. Adding ashwagandha requires a broader panel.

Recommended Lab Schedule

Baseline (before starting either agent):

• Serum total testosterone and free testosterone
• LH and FSH
• SHBG
• Estradiol (sensitive assay)
• TSH, free T3, free T4
• AM cortisol (8:00 to 9:00 AM draw)
• CBC with hematocrit
• Comprehensive metabolic panel

Week 6 follow-up:

• Repeat all of the above.
• If testosterone is above 900 ng/dL and the target was 500 to 700 ng/dL, reduce enclomiphene dose to 12.5 mg before adjusting ashwagandha, since enclomiphene is the prescription agent and has a cleaner dose-response relationship.
• If TSH is suppressed below 0.4 mIU/L, temporarily discontinue ashwagandha and recheck TSH at week 10.
• If AM cortisol is below 10 mcg/dL, order a cosyntropin stimulation test before continuing.

Week 12 and every 6 months thereafter:

• Full panel as above.
• Add PSA in men over 40 per standard testosterone therapy surveillance guidance.

Dose and Timing Considerations

No pharmacokinetic data support a mandatory separation window between enclomiphene and ashwagandha. Enclomiphene's half-life is approximately 10 hours, and ashwagandha's withanolides do not appear to alter its absorption.

Practical Dosing Guidance

A reasonable approach for most patients:

• Take enclomiphene in the morning with or without food (consistent timing matters more than fasting status).
• Take ashwagandha with the evening meal. Evening dosing of ashwagandha has been associated with improved sleep quality in trial data, and the cortisol-lowering effect may be more relevant to nighttime HPA activity.
• Use a root extract standardized to at least 5% withanolides, 300 to 600 mg/day. Higher doses do not appear to produce proportionally greater testosterone effects and increase the probability of GI side effects.
• Do not exceed 600 mg/day while on enclomiphene without explicit prescriber approval given the additive testosterone effects.

What to Tell Your Prescriber

Bring the following information to your appointment:

1. The brand and dose of ashwagandha you are taking (standardization percentage matters).
2. How long you have been taking it and whether you noticed any hormonal effects.
3. Any symptoms of elevated testosterone: acne, mood changes, nocturnal erections, or scalp hair thinning.
4. Any thyroid symptoms: palpitations, heat intolerance, or unexpected weight loss.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "Clinicians should assess and document all concurrent medications and supplements before initiating therapy to enable accurate interpretation of laboratory results and identification of potential interactions" [14]. Ashwagandha fits squarely in that category.

Evidence Quality Assessment

The evidence base for this combination is indirect. No randomized controlled trial has evaluated enclomiphene plus ashwagandha as a co-administered regimen. The individual evidence for each agent's effects is moderate-quality at best.

Ashwagandha testosterone trials are often small (N=46 to 57), industry-funded, and use proprietary extracts (KSM-66, Sensoril) that may not be equivalent to commercial products. Enclomiphene's largest trials had N=163 to 174. Neither body of evidence reaches the standard of large Phase 3 trials like STEP-1 (N=1,961) for semaglutide. Clinicians should treat the testosterone-raising interaction as plausible and pharmacodynamically coherent, not as definitively proven.

The Natural Medicines Comprehensive Database rates the ashwagandha-testosterone interaction as "Insufficient Evidence" for a definitive safety classification but notes a theoretical interaction with androgenic drugs. The Mayo Clinic drug interaction checker lists no interaction between ashwagandha and clomiphene-class SERMs as of mid-2025, consistent with the absence of pharmacokinetic data.